Black Lungs Symptoms

Black Lung Symptoms

Black lung disease can have a variety of symptoms depending on how far the condition has progressed. In many cases, individuals with black lung do not experience any noticeable symptoms in the early stages of the disease, although they may be more susceptible to developing respiratory tract infections, such as bronchitis, during this time. This early period is commonly referred to as asymptomatic anthracosis. Over time, however, individuals affected by the condition may develop chronic coughing and shortness of breath, along with the following:

  • Airway obstruction
  • Increased production of mucus/sputum
  • Pain while breathing
  • Pulmonary hypertension

When left untreated, or with continued exposure to coal mine dust, the condition can continue to progress and cause further complications. For instance, an afflicted individual may begin to cough up blood (hemoptysis) or produce black mucus (melanoptysis). The resulting lung damage may lead to the development of chronic bronchitis, chronic obstructive pulmonary disease (COPD), lung cancer or respiratory failure.

If an individual with black lung disease also has rheumatoid arthritis, he or she may develop Caplan’s syndrome, which, in addition to the above-listed symptoms, may lead to painful and swollen joints and the development of round nodules throughout the lungs. Overall, individuals with black lung experience a significant decrease in their quality of life.

If you’re living with black lung disease and dealing with its impactful symptoms, you may be interested in cellular therapy. Please contact the Lung Institute at (800) 729-3065 to learn how our innovative cellular therapy may be able to help relieve your symptoms and potentially even slow the progression of the disease. Our goal is to help you breathe easier, and our knowledgeable team is fully equipped to answer any questions you may have.

* Every patient is given a Patient Satisfaction Survey shortly after treatment. Responses to the 11-question survey are aggregated to determine patient satisfaction with the delivery of treatment.

^ Quality of Life Survey data measured the patient’s self-assessed quality of life and measurable quality of improvement at three months of COPD patients.

All claims made regarding the efficacy of Lung Institute's treatments as they pertain to pulmonary conditions are based solely on anecdotal support collected by Lung Institute. Individual conditions, treatment and outcomes may vary and are not necessarily indicative of future results. Testimonial participation is voluntary. Lung Institute does not pay for or script patient testimonials.

As required by Texas state law, the Lung Institute Dallas Clinic has received Institutional Review Board (IRB) approval from MaGil IRB, now Chesapeake IRB, which is fully accredited by the Association for the Accreditation of Human Research Protection Program (AAHRPP), for research protocols and procedures. The Lung Institute has implemented these IRB approved standards at all of its clinics nationwide. Approval indicates that we follow rigorous standards for ethics, quality, and protections for human research.

Each patient is different. Results may vary.